Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

81. Cost-effectiveness of psoriasis therapy with etanercept in Germany

Cost-effectiveness of psoriasis therapy with etanercept in Germany Cost-effectiveness of psoriasis therapy with etanercept in Germany Cost-effectiveness of psoriasis therapy with etanercept in Germany Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The study examined intermittent therapy with etanercept (25 mg twice weekly) for patients with moderate-to-severe psoriasis. Treatment lasted 12 or 24 weeks on the basis of the patients' response. Etanercept was compared with conventional non-systemic therapy, which comprised purely topical treatment. Type of intervention Treatment. Economic study type Cost-utility analysis Study population The study population

NHS Economic Evaluation Database.2007

82. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(28): 1-158 Authors' objectives "The objectives of this review were to assess the comparative clinical effectiveness

Health Technology Assessment (HTA) Database.2007

83. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis (...) and review of comparative clinical- and cost-effectiveness Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis

Health Technology Assessment (HTA) Database.2007

84. Long-term clinical and cost-effectiveness of infliximab and etanercept for rheumatoid arthritis

Long-term clinical and cost-effectiveness of infliximab and etanercept for rheumatoid arthritis Long-term clinical and cost-effectiveness of infliximab and etanercept for rheumatoid arthritis Long-term clinical and cost-effectiveness of infliximab and etanercept for rheumatoid arthritis Suarez-Almazor ME, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Suarez-Almazor ME, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V. Long-term clinical and cost-effectiveness of infliximab and etanercept for rheumatoid arthritis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Overview no 29. 2007 Authors' objectives six research questions were addressed; . What is the evidence from clinical trials or observational

Health Technology Assessment (HTA) Database.2007

85. Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching

Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V, Roundtree A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V, Roundtree A. Infliximab and etanercept in rheumatoid arthritis: timing, dose escalation, and switching. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report No 86. 2007 Authors' objectives The objectives of this report were to review the available data on the treatment of Rheumatoid Arthritis (RA

Health Technology Assessment (HTA) Database.2007

86. Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness

Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen (...) M, Cox V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Suarez-Almazor M, Ortiz Z, Lopez-Olivo M, Moffett M, Pak C, Skidmore B, Kimmel B, Kallen M, Cox V. Infliximab and etanercept in rheumatoid arthritis: systematic review of long-term clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs

Health Technology Assessment (HTA) Database.2007

87. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill R A, Jones A, Mujica Mota R, Walley T CRD summary (...) This review, which assessed the clinical effectiveness of anti-tumour necrosis factor-α therapy for patients with ankylosing spondylitis, concluded that the therapy is clinically effective in the short term. The authors' conclusions are likely to be reliable. Authors' objectives To assess the comparative clinical effectiveness and cost-effectiveness of anti-tumour necrosis factor (TNF)-α therapy (adalimumab, etanercept and infliximab) for the treatment of ankylosing spondylitis. This abstract will only

DARE.2007

88. Etanercept and efalizumab for the treatment of psoriasis: a systematic review

Etanercept and efalizumab for the treatment of psoriasis: a systematic review Etanercept and efalizumab for the treatment of psoriasis: a systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

NIHR HTA programme2006

89. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2006

90. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation

NIHR HTA programme2006

91. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R CRD summary (...) This review concluded that there was some evidence, from three trials, to suggest that both etanercept and infliximab are efficacious treatments for psoriatic arthritis. Short-term benefits for joint and psoriasis symptoms and functional status were observed with both drugs, but further research is needed to assess the long-term benefits. The review was well conducted and its conclusions are likely to be reliable. Authors' objectives To assess the clinical effectiveness, safety, tolerability and cost

DARE.2006

92. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A CRD summary This review concluded that adalimumab, etanercept and infliximab are effective treatments compared with placebo for patients with rheumatoid arthritis who are not well-controlled by disease-modifying antirheumatic drugs. Combination with methotrexate seems more effective in early rheumatoid arthritis. An increased risk of infection may

DARE.2006

93. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation

Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, Wells G A Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, Wells G A. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report Issue 64. 2006 Authors' objectives The aim of this report is to provide a clinical review and economic

Health Technology Assessment (HTA) Database.2006

95. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103) Etanercept and efalizumab for the treatment of adults with psoriasis | Guidance and guidelines | NICE Etanercept and efalizumab for the treatment of adults with psoriasis Technology appraisal guidance [TA103] Published date: 26 July 2006 Share Guidance on etanercept (Enbrel) for treating severe psoriasis in adults. The recommendations also apply to etanercept biosimilar products that have a marketing authorisation (...) , because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy. As a result the 'British national formulary' has been updated to say that efalizumab should not be prescribed for patients who are not already taking it. Treatment for patients who are taking efalizumab should be reviewed. Therefore, NICE has withdrawn its guidance on the use of efalizumab for the treatment of adults with psoriasis. Guidance on the use of etanercept for the treatment of adults

National Institute for Health and Clinical Excellence - Technology Appraisals2006

96. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis Boonen A, van der Heijde D, Severens J L (...) , Boendermaker A, Landewe R, Braun J, Brandt J, Sieper J, van der Linden S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Etanercept (25 mg twice weekly) and infliximab (5 mg/kg every 6 weeks after the usual loading dose at weeks 0, 2

NHS Economic Evaluation Database.2006

97. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of etanercept in adults with rheumatoid arthritis (RA). The initial dosage was 25 mg, administered twice-weekly as a subcutaneous injection. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2006

98. Etanercept and efalizumab for the treatment of psoriasis: a systematic review

Etanercept and efalizumab for the treatment of psoriasis: a systematic review Etanercept and efalizumab for the treatment of psoriasis: a systematic review Etanercept and efalizumab for the treatment of psoriasis: a systematic review Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R Citation Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R (...) . Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technology Assessment 2006; 10(46): 1-252 Authors' objectives

The aim of this review was to evaluate the clinical effectiveness, safety, tolerability and cost-effectiveness of etanercept and efalizumab for the treatment of moderate to severe chronic plaque psoriasis.

Authors' conclusions Clinical trial data indicate that both etanercept and efalizumab are efficacious in patients who are eligible for systemic

Health Technology Assessment (HTA) Database.2006

99. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) , etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006; 10(42): 1-248 Authors' objectives This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-a (TNF-a), when used in the treatment of rheumatoid arthritis (RA) in adults. Authors' conclusions Adalimumab, etanercept and infliximab are effective

Health Technology Assessment (HTA) Database.2006